Abstract
AIDS Clinical Trials Group (ACTG) 246/946 was a double-blinded, randomized, controlled trial of HIV-1 MN rgp160 ImmunoAG vaccine in HIV-infected patients with CD4+ T cell counts ≥500 and 200-400/mm3. The main objectives were to study the safety and immunogenicity of this vaccine and to study the persistence of the immune responses after vaccination over a longer period of time. Fifteen patients with CD4+ T cell counts of ≥500/mm3 were enrolled in the ACTG 246 study. ACTG 246 patients received a monthly injection of vaccine or control for 6 months and then injections every 2 months. After completion of this study, seven new patients with CD4+ T cell counts of 200-400/mm3 entered into the ACTG 946 study. These study patients received highly active antiretroviral therapy (HAART) (ritonavir, didanosine, and stavudine) for 9 weeks to stabilize their viral load and then each patient received a monthly injection of vaccine or control substance for 6 months with HAART. The study of these two relatively small populations showed that the vaccine was safe without any adverse effect both in the patients with CD4+ T cell counts of ≥500 and 200-400/mm3. The vaccine was also immunogenic in patients with CD4+ T cell counts of ≥500/mm3 as measured by gp160-specific lymphocyte proliferative responses, and it persisted after they had received more than six vaccine injections, for a longer period of time.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1371-1378 |
| Number of pages | 8 |
| Journal | AIDS Research and Human Retroviruses |
| Volume | 17 |
| Issue number | 15 |
| DOIs | |
| State | Published - 2001 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Immunology
- Virology
Cite this
Effect of therapeutic immunization with HIV type 1 recombinant glycoprotein 160 immunoAG vaccine in HIV-infected individuals with CD4+ T cell counts of ≥500 and 200-400/mm3 (AIDS Clinical Trials Group Study 246/946). / Kundu-Raychaudhuri, S.; Sevin, A.; Kilgo, P.; Nokta, M.; Pollard, Richard B; Merigan, T. C.
In: AIDS Research and Human Retroviruses, Vol. 17, No. 15, 2001, p. 1371-1378.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Effect of therapeutic immunization with HIV type 1 recombinant glycoprotein 160 immunoAG vaccine in HIV-infected individuals with CD4+ T cell counts of ≥500 and 200-400/mm3 (AIDS Clinical Trials Group Study 246/946)
AU - Kundu-Raychaudhuri, S.
AU - Sevin, A.
AU - Kilgo, P.
AU - Nokta, M.
AU - Pollard, Richard B
AU - Merigan, T. C.
PY - 2001
Y1 - 2001
N2 - AIDS Clinical Trials Group (ACTG) 246/946 was a double-blinded, randomized, controlled trial of HIV-1 MN rgp160 ImmunoAG vaccine in HIV-infected patients with CD4+ T cell counts ≥500 and 200-400/mm3. The main objectives were to study the safety and immunogenicity of this vaccine and to study the persistence of the immune responses after vaccination over a longer period of time. Fifteen patients with CD4+ T cell counts of ≥500/mm3 were enrolled in the ACTG 246 study. ACTG 246 patients received a monthly injection of vaccine or control for 6 months and then injections every 2 months. After completion of this study, seven new patients with CD4+ T cell counts of 200-400/mm3 entered into the ACTG 946 study. These study patients received highly active antiretroviral therapy (HAART) (ritonavir, didanosine, and stavudine) for 9 weeks to stabilize their viral load and then each patient received a monthly injection of vaccine or control substance for 6 months with HAART. The study of these two relatively small populations showed that the vaccine was safe without any adverse effect both in the patients with CD4+ T cell counts of ≥500 and 200-400/mm3. The vaccine was also immunogenic in patients with CD4+ T cell counts of ≥500/mm3 as measured by gp160-specific lymphocyte proliferative responses, and it persisted after they had received more than six vaccine injections, for a longer period of time.
AB - AIDS Clinical Trials Group (ACTG) 246/946 was a double-blinded, randomized, controlled trial of HIV-1 MN rgp160 ImmunoAG vaccine in HIV-infected patients with CD4+ T cell counts ≥500 and 200-400/mm3. The main objectives were to study the safety and immunogenicity of this vaccine and to study the persistence of the immune responses after vaccination over a longer period of time. Fifteen patients with CD4+ T cell counts of ≥500/mm3 were enrolled in the ACTG 246 study. ACTG 246 patients received a monthly injection of vaccine or control for 6 months and then injections every 2 months. After completion of this study, seven new patients with CD4+ T cell counts of 200-400/mm3 entered into the ACTG 946 study. These study patients received highly active antiretroviral therapy (HAART) (ritonavir, didanosine, and stavudine) for 9 weeks to stabilize their viral load and then each patient received a monthly injection of vaccine or control substance for 6 months with HAART. The study of these two relatively small populations showed that the vaccine was safe without any adverse effect both in the patients with CD4+ T cell counts of ≥500 and 200-400/mm3. The vaccine was also immunogenic in patients with CD4+ T cell counts of ≥500/mm3 as measured by gp160-specific lymphocyte proliferative responses, and it persisted after they had received more than six vaccine injections, for a longer period of time.
UR - http://www.scopus.com/inward/record.url?scp=0034755088&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0034755088&partnerID=8YFLogxK
U2 - 10.1089/088922201753197033
DO - 10.1089/088922201753197033
M3 - Article
C2 - 11679149
AN - SCOPUS:0034755088
VL - 17
SP - 1371
EP - 1378
JO - AIDS Research and Human Retroviruses
JF - AIDS Research and Human Retroviruses
SN - 0889-2229
IS - 15
ER -